American Headache Society Annual Scientific Meeting (AHS)

The associate professor of neurology at Mayo Clinic and member of the board of directors at AHS shared her perspective on the importance of collecting more information on status migrainosus and the need to develop a better approach and definition. [WATCH TIME: 3 minutes]

The director of the Montefiore Headache Center spoke about the Migraine Clinical Outcome Assessment System project and the need for better patient-reported outcome measures in migraine clinical care.

The Michael Hooker Distinguished Professor and director of the NIMH psychoactive drug screening program at University of North Carolina School of Medicine discussed the need for large placebo-controlled trials of psychedelics in migraine disorders. [WATCH TIME: 4 minutes]

Patients in the open-label extension also showed limited need for acute treatment with rimegepant (Nurtec ODT; Biohaven Pharmaceuticals), as more than 80% of patients took 16 or fewer total tablets over the 28-day period.

The neurologist at Weill Cornell Medicine and NewYork-Presbyterian Hospital offered his insight into the hot topics at the American Headache Society Annual Scientific Meeting, including a presentation on the prevalence of status migrainosus. [WATCH TIME: 4 minutes]

A retrospective review of more than 1000 electronic medical records suggests that for those with migraine, the presence of neck pain, anxiety, depression, and insomnia show no comparative differences in treatment response predictability.

The Michael Hooker Distinguished Professor and director of the NIMH psychoactive drug screening program at University of North Carolina School of Medicine shared his insight into his keynote address at the American Headache Society Annual Scientific Meeting. [WATCH TIME: 8 minutes]

The headache fellow at Cleveland Clinic outlined the design and reasoning for a new study assessing nerve blocks to treat COVID-19 headache.

The duo from Cleveland Clinic discussed their presentation from AHS 2021 regarding the effects of COVID-19 on access to telemedicine visits among minorities.

The director of the Montefiore Headache Center discussed the momentum within the migraine research community as well as some of the more notable presentations from AHS 2021.

Deena Kuruvilla, MD, the medical director of the Westport Headache Institute spoke to the potential of e-TNS in the treatment of migraine overall and which gaps in care that it might fill.

The vice president of Medical Affairs in Migraine at Impel discussed the clinical takeaways from the STOP 301 trial of intranasal DHE and the advantages that the novel formulation might offer patients with migraine.

The director of the Headache Center of Southern California discussed research opportunities for layered treatment approaches in migraine.

Neurology News Network for the week ending June 12, 2021.

The program director of the Medstar Georgetown University Hospital Headache Medicine Fellowship program discussed further research to be conducted with the nasal delivery of DHE.

The findings support previous data that showed no differences between telemedicine and traditional consultations in HIT-6 assessment scores over a long-term period.

The director for the Montefiore Headache Center discussed the COURAGE study and how to effectively use a layered treatment approach with ubrogepant and CGRP monoclonal antibodies.

A post-hoc analysis of the phase 2/3 trial of rimegepant revealed early and sustained efficacy compared to placebo, with significant reductions in weekly migraine days.

The program director of the Medstar Georgetown University Hospital Headache Medicine Fellowship program discussed the advantages of INP104 over other forms of dihydroergotamine.

Investigators conducted a 9-month study that demonstrated the correlation of the MBI, calculated as the sum of headache days times the maximum intensity of headache on each headache day, with satisfaction of migraine status.

Researchers used a connected network of studies that were generally well balanced in terms of key baseline characteristics, such as baseline MMD and use of prior therapies, to compare preventive treatments.

The director for the Headache Center of Southern California discussed his research presented at AHS 2021 which evaluated a combination of onabotunlinumtoxinA and CGRPs in patients with chronic migraine.

Recent data presented at the AHS annual meeting showed clinically meaningful improvements in MMD and MHD in patients with both chronic and episodic migraine.

A post-hoc analysis of 4 clinical trials of galcanezumab found no differences between dose groups of galcanezumab or placebo in rates of ‘wearing off’ effect.

The director of the Headache Center of Southern California provided insight on how a layered treatment approach to chronic migraine can be directly implemented into clinical care.

The director of the Montefiore Headache Center detailed the ways the Migraine Buddy app can help simplify conducting migraine clinical trials while expanding the reach of patients.

Absence of photophobia, phonophobia, and nausea were achieved in a similar percentage of perimenstrual and non-perimenstrual ubrogepant-treated attacks.

These real-world findings confirm that a 156- to 195-unit dose of onabotulinumtoxinA is efficacious and safe, consistent with findings from the PREEMPT clinical trials.

The program director of the Medstar Georgetown University Hospital Headache Medicine Fellowship program discussed the findings of the STOP 301 study.

Using the FDA-approved Cefaly device, the TEAM study data suggest that the device can be applied as a safe alternative to pharmacological treatments in the acute treatment of migraine.